Communications Biology (Dec 2021)
Deep dissection of the antiviral immune profile of patients with COVID-19
- Djordje Atanackovic,
- Stephanie V. Avila,
- Forat Lutfi,
- Diego de Miguel-Perez,
- Xiaoxuan Fan,
- Gabriela Sanchez-Petitto,
- Erica Vander Mause,
- Jonathan Siglin,
- John Baddley,
- Heather D. Mannuel,
- Hanan Alkhaldi,
- Kim G. Hankey,
- Rena Lapidus,
- Michael Kleinberg,
- Joseph Rabin,
- Carl Shanholtz,
- Christian Rolfo,
- Aaron P. Rapoport,
- Saurabh Dahiya,
- Tim Luetkens
Affiliations
- Djordje Atanackovic
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Stephanie V. Avila
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Forat Lutfi
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Diego de Miguel-Perez
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Xiaoxuan Fan
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Gabriela Sanchez-Petitto
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Erica Vander Mause
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Jonathan Siglin
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- John Baddley
- Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Heather D. Mannuel
- Hematology/Oncology, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center
- Hanan Alkhaldi
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Kim G. Hankey
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Rena Lapidus
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Michael Kleinberg
- Division of Infectious Diseases, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Joseph Rabin
- R. Adams Cowley Shock Trauma Center, Department of Surgery, University of Maryland School of Medicine
- Carl Shanholtz
- Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine
- Christian Rolfo
- University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Aaron P. Rapoport
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Saurabh Dahiya
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- Tim Luetkens
- Transplant and Cellular Therapy Program, Department of Medicine, University of Maryland School of Medicine and Greenebaum Comprehensive Cancer Center
- DOI
- https://doi.org/10.1038/s42003-021-02852-1
- Journal volume & issue
-
Vol. 4,
no. 1
pp. 1 – 12
Abstract
Atanackovic and coauthors screen COVID-19 patients for antibodies against 9 different SARS-CoV-2 proteins observing responses against the spike (S) proteins, the receptor-binding domain (RBD), and the nucleocapsid (N) protein which were of the IgG1 and IgG3 subtypes. They also characterised immune responses in these patients and their findings will help to identify the most relevant component of the anti-SARS-CoV-2 humoral immune response as well as assist the design of immunomonitoring methods for anti-COVID-19 vaccines.
